选择性免疫抑制使用介素-6受体抑制剂来管理与免疫相关的不良事件
Faisal Fa'ak1, Maryam Buni2, Adewunmi Falohun2
1Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA.
Journal for immunotherapy of cancer
|June 16, 2023
概括
与免疫检查点抑制剂 (ICI) 治疗的患者中,抗干流素-6受体 (anti-IL-6R) 治疗有效地管理了与免疫相关的不良事件 (irAEs). 这种方法显示出显著的irAE分辨率,而不会对整体瘤应答率产生负面影响.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
背景情况:
- 与免疫相关的不良事件 (irAEs) 往往需要治疗中断或停止,特别是在联合免疫检查点抑制剂 (ICI) 治疗中.
- 治理irrAEs对于保持治疗连续性和患者的治疗结果至关重要.
- 抗干乐素-6受体 (抗IL-6R) 治疗正在作为对irAEs的潜在治疗方法进行探索.
研究的目的:
- 追溯评估抗IL-6R治疗对管理irAEs的安全性和有效性.
- 评估抗IL-6R对irAE严重程度和整体瘤响应率 (ORR) 的影响.
主要方法:
- 进行了一项回顾性多中心研究,涉及92名接受抗IL-6R抗体 (托西利祖马布或沙利祖马布) 治疗的患者,这些患者在ICI后因irrAEs或自身免疫性疾病爆发而接受治疗.
- 患者的irAEs和ORR在抗IL-6R治疗前后被评估.
- 使用RECIST V.1.1标准进行瘤反应评估.
主要成果:
- 73%的患者在开始抗IL-6R治疗后的中位数为2.0个月内经历了缓解或≤1级irrAEs.
- 整体瘤应答率 (ORR) 在抗IL-6R治疗前后保持稳定,为66%.
- 在黑色素瘤患者中,在抗IL-6R治疗后,ORR从56%增加到68% (p=0.04).
结论:
- 准IL-6R代表了管理各种IRE的有效策略.
- 抗IL-6R治疗可以在不损害抗瘤免疫力的情况下进行.
- 这些发现支持正在进行的临床试验,研究与ICI结合的抗IL-6R.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
202
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
202
Immunodeficiency Diseases
998
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
There are three main causes of immunodeficiency...
998
Drugs Used in Lower Respiratory Disorders: Overview
506
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
506
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
177
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
177
T Cell Types and Functions
1.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.1K
Inflammatory Bowel Disease IV: Pharmacological Management
158
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
158


